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ABSTRACT In this review, the Basic and Translational Sciences Assembly of the European Respiratory
Society (ERS) provides an overview of the 2019 ERS International Congress highlights. In particular, we
discuss how the novel and very promising technology of single cell sequencing has led to the development
of a comprehensive map of the human lung, the lung cell atlas, including the discovery of novel cell types
and new insights into cellular trajectories in lung health and disease. Further, we summarise recent
insights in the field of respiratory infections, which can aid in a better understanding of the molecular
mechanisms underlying these infections in order to develop novel vaccines and improved treatment
options. Novel concepts delineating the early origins of lung disease are focused on the effects of pre- and
post-natal exposures on neonatal lung development and long-term lung health. Moreover, we discuss how
these early life exposures can affect the lung microbiome and respiratory infections. In addition, the
importance of metabolomics and mitochondrial function analysis to subphenotype chronic lung disease
patients according to their metabolic program is described. Finally, basic and translational respiratory
science is rapidly moving forward and this will be beneficial for an advanced molecular understanding of
the mechanisms underlying a variety of lung diseases. In the long-term this will aid in the development of
novel therapeutic targeting strategies in the field of respiratory medicine.
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CONGRESS HIGHLIGHTS
BASIC AND TRANSLATIONAL SCIENCE
Introduction
The European Respiratory Society (ERS) International Congress 2019 in Madrid brought together leading
experts in all fields of respiratory medicine and research. The Basic and Translational Sciences Assembly
organised three scientific symposia and two hot topics sessions and received 351 abstracts for the congress
in Madrid, from which 336 were accepted and presented by early career members. In line with [1], we
here summarise a selection of major scientific highlights that were discussed in Madrid 2019.
The human lung cell atlas
Single cell RNA sequencing (scRNA Seq) is a rapidly developing technology, enabling researchers to
delineate gene expression patterns of individual cells. This technology is key for the so-called human lung
cell atlas, a dynamic online platform freely accessible to the scientific community (lungcellatlas.org). The
first presentation in this session was given by Martijn Nawijn (University Medical Center Groningen,
Groningen, The Netherlands) about using sc-Seq technology to investigate the differences between
childhood onset asthmatics and healthy controls in human bronchial biopsies [2]. Single cells dissociated
from airway wall biopsies were analysed using a Droplet-based 10x Genomics (Pleasanton, CA, USA)
platform. Early results were biased towards an over-representation of airway epithelial cells compared to
the numbers seen in histology of adjacent biopsies. Comparison between disease status showed an
expected increase in the number of goblet cells in the asthmatic airways as well as a new type of
differentiated cell named “mucous ciliary cell”, that expresses both mucin and ciliary genes. To determine
the origin of this new cell type, linkage trajectory analysis was conducted, which found basal to club to
ciliated or to mucus cell trajectories. This mucous ciliated cell state was identified in asthmatics, with
active transitions between ciliated and goblet cells. T-helper cells type 2 (Th2-cells) were also found to be
increased in the asthmatic biopsies. Using cell–cell interaction analysis, using the receptor expression by
one cell and expression of the cytokine/chemokine from another; there was a shift from airway structural
cell communication in healthy lungs to a Th2-dominated interactome in asthma. This indicates that
increased mucus expression in asthma is driven by the interactions with Th2 cells through interleukin
(IL)-13 signalling and this Th2-dominated interactome might be a good candidate for potential novel
therapeutic targets.
Next, Pascal Barbry (Institut de Pharmacologie Moléculaire et Cellulaire, Valbonne, France) presented two
complementary airway in-vitro and in-vivo models: 1) a 3D model of primary airway culture of airway
epithelial cells grown at air liquid interface (ALI) to study mechanics of differentiation; and 2) data
obtained from bronchoscopy samples across different regions of the lung. ALI- grown epithelial cell
differentiation was assessed at days 7, 12, 28 and 47 of air exposure, then ran on the 10x platform. Using
t-distributed stochastic neighbour embedding (t-SNE) plots based subpopulations of cells, scRNA
expression patterns were resolved over time. A large population of airway epithelial cells with proliferative
signature was observed at the early time point of differentiation, but diminished at later time points. Using
the sample approach different cell types (such as basal and goblet cells) can be followed over the
differentiation process. Using this method, an overlap between the secretory/club and goblet cells was
identified, with an overlap between the two cell types for a number of specific markers. Furthermore, a
new type of airway cell was described, the “deuterosomal cell”, a precursor between secretory and
multiciliated cells, similar to Martijn Nawijn’s work. However, here, this cell type transition was also found
in healthy tissue. Using linkage trajectory analysis it was predicted that club cells act as precursors of
multiciliated cells and goblet cells. In addition, goblet cells may also act as precursors of multiciliated cells.
A new tissue dissociation method using a cold-active protease from Bacillus licheniformis was also
described, which allows for dissociation at cold temperatures limiting the degradation of RNA and
resulting in the collection of 80–90% viable cells [3]. By comparing gene expression throughout the airway
(nose, trachea, bronchus (5–6 division) and distal bronchus), a close relationship was found between the
trachea and bronchus, and certain cell subpopulations were specific to one region, such as macrophages to
the distal lung samples.
Joachim Schultze (University of Bonn, Bonn, Germany) presented his unpublished research on chronic
obstructive pulmonary disease (COPD) and scRNA-seq. This study used multi-colour flow cytometry for
identification and characterisation of immune cells derived from blood and bronchoalveolar lavage (BAL)
of control and Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage II COPD patients.
Due to the challenges in single cell analysis regarding cell viability and survival in droplet based methods,
a comparative analysis between a droplet-based (10x Genomics), with a gravity-based method (Seq-Well),
of scRNA-seq was performed. Mathematical integration of data obtained from samples of different
controls and patients allowed unbiased clustering of cells based on common expression profiles and
additional background cell-specific information. Machine learning-assisted cell annotation algorithms are
able to calculate the cell label probability closest to known literature. The success of this approach was
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demonstrated by confirming that neutrophils [4] and type 1 innate lymphoid cells are increased in COPD
samples [5]. After establishing, optimisation and validation of the bioinformatics analysis, myeloid cell
populations, more specifically neutrophils, monocytes and macrophages, were found to be
under-represented in the droplet-based scRNA-seq. The gravity-based method showed a higher
representation and annotation of immune cells. For example, three different clusters of neutrophils as well
as multiple alveolar macrophage populations were identified; this could both account for different cell
types or different cell states. Regarding differences between COPD and control samples, proliferating
macrophages as well as monocyte derived macrophages were increased in COPD, while macrophages
expressing genes involved in antigen processing and presentation as well as cell motility were decreased.
Confirmatory downstream studies showed a reduction in MHC class I and II molecules as well as reduced
macrophage motility in cells isolated from COPD patients. Heterogeneous but significant changes in lipid
metabolism were also present in the macrophages from COPD patients, in particular cholesterol
metabolism. In conclusion, differences in cell plasticity allow the identification of disease- and
patient-specific changes, which could explain heterogeneity in the pathophysiology of COPD.
Finally, Herbert Schiller (Comprehensive Pneumology Center Munich) presented longitudinal scRNA-seq
data for cell fate trajectory studies focusing on defective repair mechanisms and regeneration responses
after lung injury. scRNA-seq data from bleomycin injured mouse lung tissue were used to identify the
evolution of different cell types and states which could predict cell dynamics and explain human variations
observed when comparing control and end-stage lung fibrosis tissue samples. Differences in
receptor-ligand pairs predicted active cell communications over time, calculating relative proportions of
altered interactions, such as macrophages–endothelial cells as well as fibroblasts–alveolar epithelium
communications. During homeostasis, mesenchymal cell populations showed heterogeneity in the alveolar
type II cell niche. It was possible to characterise matrixfibroblasts, lipofibroblasts, pericytes,
Hedgehog-interacting protein-positive (Hhip+) fibroblasts and smooth muscle cells and to confirm this
profile by spatial validation using multiplexed single molecule in situ mRNA hybridisation [6, 7] together
with surfactant protein C fluorescent staining. During fibrogenesis, lipofibroblasts expressing transcription
factor 21 (Tcf21) appeared to be the major source of injury-induced myofibroblast in the mouse. Mouse
and human data integration showed human fibroblast subtype correspondence, but Hhip+ fibroblasts were
not matched to any of the human mesenchymal populations. Regarding injury specific alveolar epithelial
cell states, high-resolution real-time scRNA-seq revealed a squamous transient keratin 8 positive (Krt8+)
alveolar differentiation intermediate cell type [8] present only during the bleomycin fibrogenesis phase.
The state of these cells was further assessed by RNA velocity [9]. Sequential sampling over time allows the
differentiation between unspliced and spliced mRNA, distinguishing between newly synthesised versus
mature mRNA. Using this tool, Krt8+ cells were predicted to be derived from alveolar type II cells and a
new airway club cell population was characterised by very high expression of MHC class II molecules.
Traditional lineage tracing experiments further confirmed the dual origin prediction from single cell
analysis. Pseudotime trajectories showed that intermediate Krt8+ cells differentiate into terminal alveolar
type I cells. Further use of human precision-cut lung slices and organoids will allow the induction of
perturbations in the different cell populations to validate and help with new findings relevant to
degenerative lung diseases.
Finally, scRNA-seq is a promising, rapidly developing novel technology, enabling researchers to gain
important insight into cellular trajectories in lung health and disease. Furthermore, as evident from these
studies, this technology can identify novel/rare cell types in the lung, which then need to be validated and
further understood using other methods such as immunofluorescence staining.
Scientific year in review: respiratory infections
This year’s “Scientific Year in Review” session opened with the ceremony for the Romain Pauwels
Research Award. In 2019, this award presented by Glaxo Smith Kline (€ 50000) was given to Klaus
Bønnelykke (Copenhagen University, Copenhagen, Denmark) for his achievements in the field of
paediatric asthma. His research is focused on the early origins and genetic determinants of asthma, allergy
and eczema, and has resulted in identification of susceptibility genes and other risk factors for these
diseases. He performed the first genome-wide association study of severe asthma exacerbations in early
childhood, showing the relevance of phenotyping for identification of mechanisms [10]. This study
identified CDHR3 as a susceptibility gene, and later Dr Bønnelykke provided evidence that the gene
product of CDHR3 functions as a rhinovirus C receptor [11]. Furthermore, he is co-principal investigator
of the COPSAC2010 birth cohort.
Following the award ceremony, four expert speakers discussed the newest research on respiratory
infections. Simon Jochems (Leiden University Medical Center, Leiden, The Netherlands) covered the
innate and adaptive immune responses against Streptococcus pneumoniae, the most common cause of
https://doi.org/10.1183/23120541.00350-2019 3
BASIC AND TRANSLATIONAL SCIENCE | N.D. UBAGS ET AL.
pneumonia in humans. Over 100 serotypes are currently known, and 50% of children and 10% of adults
are colonised with S. pneumoniae [12], protecting them from infection due to pre-existing immunity.
Dr Jochems uses the pneumococcal challenge model, a controlled infection of healthy volunteers with
80000 colony forming units (cfu) of S. pneumoniae via the nostrils. As bacterial pneumonia is one of the
main causes of death after influenza virus infection, the group exposed healthy volunteers to either saline
fluid or live attenuated influenza vaccine (LAIV) 3 days prior to the S. pneumoniae application and
investigated the resulting anti-bacterial immune response. The LAIV pre-application induced a transient,
10-fold increase in the S. pneumoniae density in the nose. Nasal cytokine measurements revealed that
LAIV treatment alone caused high inflammation, while S. pneumoniae application did not [13]. Increased
levels of Interferon gamma-induced protein after LAIV were found to be associated with a higher
S. pneumoniae density and were predictive of S. pneumoniae colonisation, while the opposite was observed
for IL-10. Furthermore, LAIV application impaired neutrophils’ ability to kill invading S. pneumoniae, and
monocyte invasion in the nose to clear the infection, resulting in a higher bacterial density of
S. pneumoniae. This could explain why bacterial infections after influenza are more severe.
In a second study the group investigated nasal biopsies after S. pneumoniae challenge of healthy volunteers
to find immune markers that stratify protected patients versus non-protected ones [14]. The biopsies were
analysed by CyTOF mass cytometry, allowing up to 38 cellular markers to be analysed on single cell
suspensions. Seven distinct immune cell clusters (three B-cell clusters and four CD8+ T-cell clusters) were
higher in patients who were protected from S. pneumoniae colonisation and thus may serve as predictive
markers in the future.
Simone Joosten (Leiden University Medical Center) discussed innate immune memory to improve
respiratory health. The innate immune system has classically been thought to be non-specific, and lacking
the potential to build up immunological memory. However, this dogma has recently been challenged by
several studies using the Bacillus Calmette Guérin (BCG) vaccine [15–17]. BCG vaccination modulates
non-specific immune responses against many pathogens, not only tuberculosis [18]. The exact
mechanisms of this heterogenic and incomplete protection are still unknown [19, 20]. In mice BCG
vaccination has the potential to protect against secondary infections in addition to mycobacteria [21–23],
which has also been observed in newborn children [24, 25]. Growing literature suggests that the resistance
to secondary infections after BCG vaccination cannot only be attributed to the adaptive immune system.
Dr Joosten presented a study in which the BCG vaccine was shown to induce expansion of haematopoietic
stem cells (HSCs) as well as to induce changes in their gene expression in the bone marrow. These
modified HSCs generated “trained” monocytes/macrophages that possessed enhanced anti-mycobacterial
capacity [15]. Further, respiratory viral infection can induce long-lasting memory in alveolar macrophages
[26]. The exact mechanisms are currently unknown, however, Simone Joosten highlighted several different
pathways [27, 28]. She explained that a “defence ready state” includes high glycolysis, increased expression
of cytokines, MHC II, defence genes and increased effector responses (e.g. bacterial killing). Although big
steps towards understanding the exact mechanism of BCG-induced trained immunity have been made,
there is still a big knowledge gap and further studies are needed. Eventually, training of innate immunity
may be employed in therapeutic strategies [29].
Sebastian Johnston (Imperial College London, London, UK) completed the session by presenting research
on the interaction of bacterial and viral infections during COPD exacerbations. As severe exacerbations are
responsible for decreased survival rates among COPD patients, it is critical to develop new and better
prevention strategies [30]. Historically, the importance of viral and bacterial infections in precipitating
COPD exacerbations has been underestimated [31]. More recently, it was found that bacterial infections,
and possibly more importantly, viral infections (detected in 52% of patients with acute exacerbations) are
associated with exacerbations and that viral infections can potentially trigger secondary bacterial infections
[32–34]. Sebastian Johnston suggested that increased airway glucose levels detected in COPD patients,
which were further increased during acute exacerbations, may be a mechanism through which rhinoviruses
enhance bacterial growth [33]. COPD patients treated with inhaled corticosteroids (ICS) have an increased
risk of pneumonia and Sebastian Johnston presented that ICS treatment resulted in suppressed immune
responses, including decreased levels of interferons and secretory leukocyte protease inhibitor (SLPI),
impaired virus control, increased bacterial load, and increased mucin levels upon rhinovirus infection [35].
Treatment of mice with exogenous interferon-β reversed the bacterial load and restored anti-viral activity
[35]. ICS treatment also altered the lower respiratory microbiota, impairing pulmonary bacterial control in
both human and mouse models, in which cathelicidin/LL-37 was shown to play a central role [36]. LL-37
levels were lower in sputum from COPD patients and negatively correlated with exacerbation severity and
bacterial load. Taking together, viral and bacterial infections in COPD patients may play a greater role in
triggering acute exacerbations than previously thought, and specific treatments such as interferon-β,
anti-viral treatment or cathepsin D inhibitors may potentially help to prevent acute COPD exacerbations.
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In the concluding panel discussion, the importance of using experimental infection models, and analysing
samples from different locations within the upper and lower respiratory tract, including nasal samples and
concentrated BAL fluid samples, and the timing of sampling were discussed. Other challenges such as
investigating the interaction between adaptive and innate immunity, utilising available omic-platforms,
were mentioned. In summary, this session showed that there is an urgent need to better understand the
pathogenesis and underlying molecular mechanisms of infections of the airways and of viral/bacterial
interactions, to develop effective vaccines and novel treatments. As evidenced above, this knowledge can
help to understand and maybe even prevent infectious exacerbations of lung diseases.
Early origins of lung disease: an interdisciplinary approach
This session focused on the mechanisms underlying healthy and abnormal early lung development as well
as the impact of immune maturation and the microbiome on lung health and disease.
Alan Jobe (Cincinatti Children’s Hospital, Cincinatti, OH, USA) presented an overview on the impact of
pre- and postnatal exposures on fetal and neonatal lung development. Pre-conceptional, fetal and early
childhood factors all influence lung development. These factors include epigenetic modifications, nutrition,
toxic exposures, lung and gut microbiome and other specific exposures related to pregnancies [37].
Growth-restricted infants have significantly lower lung function at 8–9 years of age compared with term
infants of normal birthweight [38]. It was also shown that infants who were small relative to their
gestational age (defined as fetal weight or birth weight <10th percentile) had higher mortality rates [39]
and increased bronchopulmonary dysplasia (BPD) [40]. Prematurity is associated with increased risk for
asthma, pneumonia and acute bronchiolitis [41, 42]. A recent meta-analysis showed that very preterm
infants (<1500 g) have lower IQ values than term infants [43] which could be related to dysregulated
maturation following preterm delivery.
Over the past 40 years, off-target exposures of fetus to steroids have occurred during pre-viable deliveries
(<24 weeks), 24–34 weeks of gestation, 34–36 weeks of gestation (according to the recommendations in the
USA but not in Europe) and elective C-section delivery. These off-target exposures may negatively affect
lung function. While inducing early lung maturation, antenatal steroids delay alveolarisation, leading to
shrinkage of the mesenchyme before the surfactant level is increased. In order to understand which steroid
exposure will stimulate lung maturation, Alan Jobe’s group has used sheep and in monkey models [44, 45].
It was concluded that different outcomes, e.g. inflammatory responses, depend on the time of exposure to
corticosteroids, and that these outcomes could be ablated by early induction of inflammation, in a similar
process as induction of tolerance to inflammatory stimuli.
Anne Hilgendorff (Comprehensive Pneumology Center Munich) covered two different aspects of
premature lung ageing: organ and cellular function. With respect to organ function, physiologic lung
ageing is characterised by chest wall and thoracic spine deformities, senile emphysema, reduced respiratory
muscle strength, increased alveolar dead space, functional changes of the airway receptors (response to
drugs decreases) and diminished ventilator response to hypoxia and hypercapnia [46]. Therefore,
physiologic lung ageing has to be taken into account when BPD infants are ageing. BPD relates to
additional features of COPD as was shown by magnetic resonance imaging, where lung structural changes
similar to COPD and lung fibrosis were observed in preterm infants with BPD [47]. Moreover, there is
severe alteration of vasculature, preceding even the mildest forms of COPD [48], suggesting BPD will
develop into COPD in later life. The underlying mechanisms leading to accelerated ageing in the COPD
lung are however still poorly understood.
Remarkably there are various hallmarks of cellular ageing seen in BPD, such as inflammation, stem cell
exhaustion, telomere dysfunction, epigenetic changes and senescence [46, 49, 50]. Anne Hilgendorff’s
group showed that prenatal smoke exposure induced a vast influx of monocytes into the lungs of fetal
mice and this led to severe matrix changes. Another study demonstrated that neonatal mice receiving
mechanical ventilation with oxygen-rich gas (MV-O2) had increased rates of endothelial cell apoptosis,
which was aggravated in mice heterozygous (lacking one allele) for the growth factor platelet-derived
growth factor receptor alpha (PDGF-Ra). Vascular and alveolar defects were due to reduced PDGF-Ra
expression, activation of which supports endothelial survival [51]. Another factor involved in BPD
pathophysiology is the monocytic receptor SIGLEC14, which has also been associated with increased risk
of COPD exacerbation [52]. Besides inflammation, stem cell exhaustion may affect postnatal lung
maturation and development, where mesenchymal stem cells fail to form the niche properly in BPD [53].
Exhaustion of airway basal progenitor cells has been implicated in early and established COPD [54].
Further, children with BPD have shorter telomere length, a biological ageing indicator, which has been
linked to reduced lung function [55]. Despite these similarities, it is still unclear how premature lung
ageing relates to lung disease. We need to understand which cells are over-proliferative and which ones are
apoptotic, and which mechanisms to stop and which ones to enable.
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Clare Lloyd (Imperial College London) reviewed the influence of early life pulmonary immunity on the
development of paediatric inflammatory respiratory disease. Severe therapy-resistant asthma (STRA) in
children is characterised by poor disease control despite maximal treatment doses and optimal assessment
of modifiable factors. Although allergic asthma is generally considered a Th2-mediated disease, emerging
evidence suggests that non-Th2 mechanisms may contribute, specifically to severe disease. Paediatric
STRA is characterised by high pulmonary interleukin (IL)-33 levels despite maximal treatment with
steroids [56]. Prof. Lloyd’s group recently described the role of innate lymphoid cells (ILCs) in paediatric
patients with severe asthma. Type 2 ILCs (ILC-2) expressing the prostaglandin receptor CRTH2 and IL-13
were found to be increased in the sputum of paediatric STRA patients compared to non-asthmatic controls
and paediatric patients with difficult asthma (i.e. poor control despite maximal treatment doses) [57].
Although CRTH2+ IL-13+ ILCs were increased in STRA at baseline, they decreased following high-dose
systemic steroid treatment, suggesting that these cells are steroid responsive. ILC2s mainly accumulate in the
peribronchial and perivascular areas of the lung following an acute inflammatory exposure [58]. Moreover,
ILC2s were proven to move faster and over longer distances compared to CD4+ T-cells. The ILC2 motility
in the lung was promoted by extracellular matrix proteins, such as collagen-I, collagen-IV and fibronectin.
Collagen-I was shown to influence the shape of the ILC2 towards a pro-migratory exploratory phenotype
that is critical for the regulation of eosinophilic inflammation.
Debby Bogaert (University of Edinburgh, Edinburgh, UK) discussed the important concept that age
matters in the development of early life pulmonary immunity. The age at which an individual is exposed
to a certain stimulus may determine how the immune response develops. The respiratory microbiome,
which starts to develop from birth onwards [59], may play a crucial role and is influenced by a variety of
host and environmental factors in early life [60]. Debby Bogaert presented data from a prospective birth
cohort study (Microbiome Utrecht Infant Study (MUIS)) demonstrating that decreased stability of
nasopharyngeal microbial communities in the first 3.5 months of life is associated with an increased
susceptibility to respiratory tract infections (RTI) in the first year of life [61]. The presence of a virus (even
asymptomatic) before the first month of life was associated with earlier and recurrent infections. Analysis
of paired nasopharyngeal and oropharyngeal samples from the MUIS study cohort from birth until
6 months of age revealed a significant overlap in bacterial composition between the two different locations
directly after birth, suggestive of similar source communities [62]. Following the first week of life, the
developmental trajectories of the oropharynx and nasopharynx niches rapidly differed and became
populated by niche-specific communities over time. The nasopharyngeal microbiome remains the key
community that drives respiratory health and infections [61], since oral microbiome composition at
1 month of life was not predictive for the number of RTI in the first year of life [62]. Analysis of the
topographical differentiation between oropharynx and nasopharynx revealed a gradual increase over the
first 3 months of life. A complete loss of topographical differentiation was observed during RTI,
suggesting the niches to become more similar. In order to predict severity of lower RTI (LRTI) in
children, the group of Debby Bogaert developed a prediction model using machine learning on samples
(paired nasopharyngeal and endotracheal aspirates) and data obtained from the paediatric intensive care
unit cohort [63]. A combination of both viral and bacterial biomarkers with host factors in a sparse
random forest analysis allowed for a high classification accuracy of LRTI samples, which were compared
to samples from healthy controls. Important disease predictors were presence of respiratory syncytial
virus, high abundance of Haemophilus influenza, H. haemolyticus, S. pneumoniae and Pseudomonas
fluorescens and low abundance of Moraxella species, antibiotic treatment in the preceding 6 months and
lack of breastfeeding [63]. These results suggest that the potential use of a microbiota-based diagnostic
or classification tool, after validation in independent cohorts, could be useful for clinical applications
in the future.
Taken together, early life (pre- and postnatal) exposures and their effects on lung development may set
the stage for (chronic) respiratory disease development in later life. Furthermore, microbiota analysis and
the identification of viral and bacterial biomarkers for the prediction of respiratory infections in early life
can lead to the development of diagnostic or classification tools, possibly contributing to prevention of
respiratory infections in early life.
Metabolic alterations in lung ageing and disease
Metabolomics is a powerful technology capturing metabolic changes in health and disease. The advantage
lies in its ability to integrate the crosstalk of multiple compartments. Craig Wheelock (Karolinska Institute,
Stockholm, Sweden) discussed the so-called “metabotype” which is influenced by genome, microbiome
and exposome (representing the sum of all expositions), thereby creating a snapshot of the patient´s
phenotype. The metabotype has the potential to discriminate health and disease states as well as distinct
clinical phenotypes. It has been analysed within the U-BIOPRED study in which the molecular phenotype
of severe asthma was investigated in an adult and a paediatric cohort. A cluster of urine metabolites was
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used to distinguish severe and mild asthma from healthy controls. In severe asthmatic patients, this
metabotype is stable upon longitudinal sampling. Comparing serum and urine metabolome revealed
metabolically distinct subphenoytpes for moderate and severe asthmatics influenced by steroid treatment
[64], indicating that the metabotype is sensitive to therapeutic regiments. Metabotypes vary in different
chronic lung diseases such as COPD [65] and BPD with similar biochemical and metabolic shifts in both
sexes, but much stronger in females than males. Many of the detected metabolites in metabolomics are
microbiome-based, thus understanding the gut–lung axis is vital to decipher the role of the metabolites in
the development of lung disease.
Peter Barnes (Imperial College London) reviewed the idea that COPD can be regarded as a disease of
accelerated ageing including metabolic alterations associated with elevated levels of cellular senescence [66].
Senescent cells remain metabolically active, secreting a mixture of pro-inflammatory cytokines, chemokines
and proteases, known as the senescence-associated secretory phenotype, mirroring the inflammatory
secretome in COPD [67]. Removal of senescent cells of the lung using senolytics, which induce apoptosis
in senescent cells, might be a promising therapeutic approach for COPD as indicated by the first human
trial in IPF [68].
Ageing and COPD are also characterised by mitochondrial alterations with increased mitochondrial mass
in the aged and COPD lung due to impaired mitophagy upon dysregulation of the PINK1/Parkin axis,
resulting in elevated numbers of fused and swollen mitochondria [69]. Basal and maximal respiration of
mitochondria are reduced in smooth muscle cells from COPD patients [70]. Aged mitochondria can
induce activation of the inflammasome via release of their DNA [71].
Philip Hansbro (University of Technology Sydney, Sydney, Australia) presented data on altered
immunometabolism and mitochondrial dysfunction in COPD, using a novel mouse model of intranasal
cigarette smoke exposure [72]. Damaged mitochondria release mitochondrial reactive oxygen species
(mROS) [73], which may further exacerbate accelerated ageing and mitochondrial damage. Usually,
mROS, a major by-product of oxidative phosphorylation, are removed by antioxidants such as hydrogen
sulphide (H2S) [73]. H2S is an endogenous mitochondrial specific antioxidant, which is both
mitochondrial protective and anti-inflammatory [74]. H2S has been reported to be reduced in both human
COPD and COPD mouse models [75, 76], suggesting that the loss of this antioxidant contributes to
disease pathology. Novel H2S donors, such as AP39 and RT-O, reduced cigarette smoke-induced ROS
levels in vitro in an epithelial ALI culture model and reduced inflammatory cell numbers in the lung and
markers of fibrosis in vivo in intranasally smoked mice. Treatment with other antioxidants, such as the
mitochondrial-targeted peptide SS-31 and the Nrf2-activating itaconate, showed similar protective effects
[71, 72, 74–77]. Thus, mROS scavengers, including mitoQ, SKQ and mitoTempo, may be considered as
new potential therapeutics for COPD treatment [70, 78].
An important cellular player regarding mitochondrial dysfunction and lung ageing are macrophages,
which display phenotypic changes and defective phagocytosis in COPD [79]. In the intranasal cigarette
smoke model, macrophages secreted higher levels of TNF-α and IL-1β and the inflammatory macrophage
marker, MARCO, was elevated on the cell surface. In the early stages of the model, macrophages showed a
decrease in glycolysis rates but an increase in both glycolysis and oxidative phosphorylation after 8 weeks.
Inhibition of glycolysis using 2DG glucose reduced inflammation and BAL inflammatory cell infiltrates,
suggesting a pathogenic role for metabolic reprogramming of macrophage in cigarette smoke-induced lung
inflammation. An increase in mitochondrial mass was also observed in CD11B+ macrophages, indicating
the potential presence of defective mitophagy or increased mitofusion. Understanding how dysregulated
mitochondrial function contributes to proinflammatory macrophage function during COPD pathogenesis,
and targeting these macrophages therapeutically, may help to reduce the inflammation present in the
COPD lung.
Anna Krasnodembskaya (University of Belfast, Belfast, UK) outlined that proper functioning of
macrophages and epithelial or various other cells, can be affected by mesenchymal stromal cells (MSC)
transferring their mitochondria via tunnelling nanotubes or extracellular vesicles [80]. Mitochondria
derived from MSCs are able to enhance the phagocytic activity of alveolar macrophages in vivo. Inhibition
of the formation of tunnelling nanotubes abrogated the effects of MSCs on macrophage phagocytosis in
vitro and their anti-microbial effects in vivo. However, inhibiting formation of tunnelling nanotubes in
MSCs did not fully block mitochondrial transfer, suggesting an additional mitochondrial transfer
mechanism via extracellular vesicles [81].
Inflammatory macrophages that had been exposed to either lipopolysaccharide or BAL fluid samples
derived from acute respiratory distress syndrome (ARDS) patients, showed increased uptake of
mitochondria derived from MSCs and enhanced oxidative phosphorylation and ATP production, when
incubated with conditioned media from MSCs. This was dependent on the mitochondrial activity of the
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MSCs, as MSCs with defective mitochondrial respiration were no longer able to activate the respiratory
function in inflammatory macrophages, which was also confirmed in an in vivo model of ARDS [82].
Taken together, within an inflammatory environment in the lung, mitochondrial transfer may lead to
metabolic reprogramming of macrophages towards an anti-inflammatory phenotype with enhanced
phagocytic activity.
In conclusion, metabolomics and the analysis of mitochondrial function are emerging as a powerful
approach to reveal metabolic reprogramming in subtypes of chronic lung diseases. Phenotyping of
subgroups of patients as well as further stratifying according to sex seems to be required to identify small
changes in metabotypes and metabolic alterations, which may offer new therapeutic options for lung
disease.
Concluding remarks
The basic and translational science sessions at the ERS Congress presented important scientific advances
in the respiratory field. The large interest of both, basic researchers and clinical scientists highlights the
importance of translational science in driving an advanced molecular understanding of lung diseases for
the development of novel therapeutic targeting strategies.
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